Objective-Human genetic variants near the FADS (fatty acid desaturase) gene cluster (FADS1-2-3) are strongly associated with cardiometabolic traits including dyslipidemia, fatty liver, type 2 diabetes mellitus, and coronary artery disease. However, mechanisms underlying these genetic associations are unclear. Approach and Results-Here, we specifically investigated the physiological role of the Δ-5 desaturase FADS1 in regulating diet-induced cardiometabolic phenotypes by treating hyperlipidemic LDLR (low-density lipoprotein receptor)-null mice with antisense oligonucleotides targeting the selective knockdown of Fads1. Fads1 knockdown resulted in striking reorganization of both ω-6 and ω-3 polyunsaturated fatty acid levels and their associated proinflammatory and proresolving lipid mediators in a highly diet-specific manner. Loss of Fads1 activity promoted hepatic inflammation and atherosclerosis, yet was associated with suppression of hepatic lipogenesis. Fads1 knockdown in isolated macrophages promoted classic M1 activation, whereas suppressing alternative M2 activation programs, and also altered systemic and tissue inflammatory responses in vivo. Finally, the ability of Fads1 to reciprocally regulate lipogenesis and inflammation may rely in part on its role as an effector of liver X receptor signaling.
H uman genetic studies have transformed cardiometabolic drug discovery, providing an unparalleled prediction tool for identification of new drug targets. This is exemplified by the recent success story of large-scale genetic studies leading to rapid development of monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 for hyperlipidemia and cardiovascular disease. 1 Given the target prediction power of human genetics, large consortium genome-wide association study efforts have identified hundreds of genomic loci linked to cardiometabolic disease traits, providing a refined list of new drug targets. However, many genome-wide association studies have identified loci containing genes of unknown function. Single nucleotide polymorphisms in the FADS (fatty acid desaturase) gene cluster (FADS1-2-3) have been repeatedly identified in genome-wide association studies across the cardiometabolic disease spectrum, including strong associations with obesity, type 2 diabetes mellitus, dyslipidemia, nonalcoholic fatty liver disease, liver enzyme elevation, coronary artery disease, and heart rate. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, mechanisms by which FADS1-2-3 polymorphisms link to these comorbid disease phenotypes are unclear. Given that expression quantitative trait loci studies have revealed altered expression of FADS1 in several of these human genetic studies, we set out to investigate the specific role of FADS1 in regulating dietinduced cardiometabolic phenotypes in hyperlipidemic mice.
See accompanying editorial on page 6
FADS1 is the only mammalian Δ-5 FADS enzyme capable of producing the important polyunsaturated fatty acids (PUFAs) arachidonic acid (AA) and eicosapentaenoic acid (EPA) from substrates dihomo-γ-linolenic acid and eicosatetraenoic acid (ETA), respectively. 13, 14 Downstream enzymatic and nonenzymatic oxidation of FADS1 product PUFAs (AA and EPA) generates diverse lipid signaling mediators that coordinate both the initiation and resolution phases of inflammatory processes. [15] [16] [17] [18] In general, AA-derived eicosanoids are thought to initiate and potentiate proinflammatory responses, 15, 16 whereas EPA-and docosohexaenoic acid (DHA)-derived mediators function in direct opposition to resolve inflammation and initiate wound healing and tissue regenerative responses. 17, 18 In particular, lipoxins, resolvins, and protectins are important lipid autacoids with varying structures and functions that are collectively defined as specialized proresolving lipid mediators (SPMs) for their ability to actively resolve inflammation. 17 ,18 Given FADS1's unique position as the sole enzymatic source of endogenous AA and EPA, we hypothesized that Fads1 loss of function would dramatically alter both proinflammatory and proresolving lipid mediators to impact diseases of unresolved inflammation such as atherosclerosis, obesity, insulin resistance, and steatohepatitis. Metabolic phenotyping of global Fads1 −/− mice has been limited because of the fact that these mice are only viable for ≈ 8 to 12 weeks without supraphysiological supplementation of AA and EPA in the diet. 19, 20 To overcome this barrier, here we used secondgeneration antisense oligonucleotides (ASOs), which predominately target liver, adipose tissue, and cells within the reticuloendothelial system to selectively knockdown Fads1 in adult hyperlipidemic mice, thereby circumventing postnatal lethality of global Fads1 deletion. We hypothesized that the underlying mechanism by which FADS1 polymorphisms alter cardiometabolic disease phenotypes is by determining the balance of endogenous AA and EPA substrates available for the production of SPMs, thereby impacting the proper resolution of inflammation. To specifically address whether endogenous EPA production by Fads1 is necessary for SPM generation and inflammation resolution, we provided a subset of mice a diet enriched in ω-3 precursor fatty acids.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Fads1 Is a Key Determinant of Membrane Phospholipid Composition and Proinflammatory Versus Proresolving Lipid Mediator Balance
To understand the role of Fads1 in maintaining membrane lipid composition and lipid mediator balance in the context of cardiometabolic disease, we used an in vivo ASOmediated knockdown approach 21 in hyperlipidemic LDLR (low-density lipoprotein receptor)-null mice. To selectively alter proinflammatory versus proresolving lipid mediator balance in the context of Fads1 loss of function, mice were also fed synthetic diets specifically designed to provide low or high levels of the ω-3 FADS1 substrate fatty acid ETA ( Figure IA in the online-only Data Supplement) as described previously by Shewale et al. 22 Fads1 ASO treatment resulted in selective knockdown of hepatic Fads1 mRNA, without altering Fads2 or Fads3 mRNA expression ( Figure 1A ). In agreement with selective Fads1 knockdown, Fads1 ASO treatment resulted in plasma accumulation of the FADS1 ω-6 substrate dihomo-γ-linolenic acid and ω-3 substrate ETA in a diet-specific manner ( Figure IB in the online-only Data Supplement). Similar dietspecific changes in FADS1 substrate (dihomo-γ-linolenic acid and ETA) and product (AA and EPA) fatty acids were seen in the liver of Fads1 ASO-treated mice, where PUFA biosynthesis is known to be most active ( Figure 1D and 1E) . Strikingly, when mice were fed a diet enriched in ω-3 PUFA precursors for ETA biosynthesis, Fads1 knockdown resulted in >80% of the total phospholipid fatty acid pool containing ETA ( Figure 1D ). This was associated with reciprocal reductions in the ω-3 FADS1 product EPA in total hepatic phospholipids ( Figure 1D ). This FADS1 substrate/product shift was also seen in several phospholipid classes including phosphatidylethanolamines and phosphatidylcholines ( Figure 1E ; Figure IC in the online-only Data Supplement). These results suggest that Fads1 is a major contributor to membrane phospholipid remodeling under certain dietary conditions. Given the fundamental roles that AA and EPA play in lipid mediator production, we next quantified a wide array of proinflammatory and proresolving lipid mediators in the liver ( Figure 1F through 1J). Global lipid mediator product profiles were clearly distinct for both dietary and genetic (Fads1) interventions. In mice fed the diet enriched ω-3 PUFA precursors, a clear shift in the production of SPMs was observed ( Figure 1F through 1J ). In the presence of the ω-3 PUFA substrate diet, Fads1 knockdown resulted in a clear imbalance between proinflammatory and proresolving lipid mediators that would be predicted to oppose proper inflammation resolution. When broadly comparing the ratio of 5-lipoxygenasederived SPMs to the proinflammatory mediator leukotriene B 4 , Fads1 knockdown skews toward a more proinflammatory and less proresolving mediator profile ( Figure 1J ; Figure 
Fads1 Reciprocally Regulates Hepatic Inflammation and Lipogenesis
In parallel to the observed imbalance between proinflammatory and proresolving lipid mediators, mice treated with Fads1 ASO develop pathological histology and gene expression signatures that are characteristic of chronic hepatic inflammation (Figure 2A through 2E). Fads1 ASO-treated mice exhibited abnormal appearance of foamy histiocyte clusters that were significantly increased in mice fed the ω-3 PUFA substrate diet (Figure 2A and 2B). Fads1 knockdown was also associated with increased expression of macrophage-selective genes including Cd68 (cluster of differentiation 68), IL-6 (interleukin-6), and Mip-1α (macrophage inflammatory protein 1 α; Figure 2C through 2E). It is important to note that Fads1 ASO-driven hepatic inflammation was most apparent in mice fed the ω-3 PUFA substrate diet (Figure 2A through 2E) , a condition where the ratio of 5-lipoxygenase-derived SPMs to leukotriene B 4 is dramatically decreased ( Figure 1J ). In addition to effects on hepatic inflammation, Fads1 knockdown was also associated with reorganization of hepatic lipid metabolism that extends beyond the scope of direct effects on PUFA biosynthesis. Fads1 knockdown resulted in reduced hepatic triglycerides in mice fed the ω-3 PUFA substrate diet ( Figure 2F ), whereas increasing phosphatidylcholine, free cholesterol and cholesteryl ester levels ( Figure Collectively, these data suggest that Fads1 knockdown limits hepatic fatty acid synthesis, adipose tissue expansion, and glucose intolerance, while promoting hepatic inflammation under dietary conditions that favor an imbalance of proinflammatory and proresolving lipid mediators.
Fads1 Knockdown Promotes Dyslipidemia and Atherosclerosis in a Diet-Specific Manner
Polymorphisms in the FADS1-2-3 gene cluster have been repeatedly associated with plasma lipids and other cardiovascular disease risk factors, 2-12 yet whether FADS1-driven Δ-5 desaturation underlies these genetic associations has remained elusive. Selective ASO-mediated knockdown of Fads1 trended (P=0.06) toward promoting aortic root atherosclerosis in saturated fat-fed mice, and significantly increased aortic root lesion size in mice fed the ω-3 PUFA substrate diet ( Figure 3A and 3B). In agreement with effects in the aortic root, Fads1 knockdown increased cholesteryl ester levels in whole aortae of mice fed the ω-3 PUFA substrate diet, and also trended toward elevating aortic free cholesterol levels ( Figure 3C and 3D). In contrast, Fads1 knockdown did not significantly alter the total necrotic core area on either dietary background ( Figure 3E and 3F). Figure 1 Continued. F, Volcano plot of all metabolites detected with the larger circles that are labeled representing metabolites that exceed the minimum thresholds for significance (P<0.05) and fold change (2> or <2). Lipid mediators that were significantly increased in ω-3 diet-fed animals are blue and appear in the shaded region, whereas those that were significantly decreased are white; n=5 per group. G, Volcano plot of all metabolites detected with the larger circles that are labeled representing metabolites that exceed the minimum threshold for significance (P<0.05) and fold change (2> or <2). Lipid mediators that were significantly decreased by Fads1 antisense oligonucleotides (ASO) are white and appear in the shaded region, whereas those that significantly increased are blue; n=5 per group. H, Partial least squares-discriminant analysis 2-dimensional scores plot demonstrated clustering of samples into distinct and separate groups based on both diet and ASO. I, Venn diagram displaying the lipid mediators that were significantly increased by ω-3 diet with control ASO in the blue circle and those that were significantly decreased by Fads1 ASO while on ω-3 diet in the gray circle. Those metabolites in the overlapping region both increased on ω-3 diet and were decreased by Fads1 ASO; n=5 per group. J, Left, Combined levels of 5-lipoxygenase (5-LOX)-derived specialized proresolving lipid mediators (SPM) are shown for each diet and treatment group. SPM included in this index are resolvin (Rv) D1, 17R-RvD1, RvD2, 17R-RvD3, RvD4, RvD6, RvE1, RvE2, lipoxin (LX) A 4 , 15R-LXA 4 , LXA 5 , LXB 4 , and LXB 5 ; n=5 per group. Graph displays mean±SEM. Middle, Levels of leukotriene B 4 (LTB 4 ). Only 1 of the 5 samples in the group fed a control diet and treated with Fads1 ASO contained LTB 4 above the limit of detection (0.1 pg) and thus the entire group was omitted; n=3 to 5 per group. Graph displays mean±SEM. Statistical significance is determined by t test. #P<0.05 control ASO vs Fads1 ASO. Right, The ratio of 5-LOX-derived SPM to LTB 4 is shown for mice on ω-3 rich diet exposed to control or Fads1 ASO; n=5 per group. Graph displays mean±SEM. Statistical significance is determined by t test. #P<0.05 control ASO vs Fads1 ASO). For A through C and E, graphs display mean±SEM. Statistical significance is determined by 2-way ANOVA. *Significantly different from the control ASO-saturated and monounsaturated fatty acid (SFA)-rich diet group (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001); #Significantly different from control ASO group within the ω-3 substrate diet group (#P<0.05, ##P<0.01, ###P<0.001, ####P<0.0001). Unlike the significant effects on hepatic triglyceride levels ( Figure 2F and 2J through 2M), Fads1 knockdown resulted in very minor alterations in plasma triglycerides, producing a transient triglyceride lowering effect that was only apparent at 8 weeks of dietary induction ( Figure 3G ). Given that very LDL triglyceride secretion rates were not significantly altered by Fads1 knockdown ( Figure VI in the online-only Data Supplement), the alterations in plasma triglyceride and cholesterol levels observed in Fads1 ASO-treated mice likely arise from altered intravascular metabolism and turnover of apoB-containing lipoproteins. Interesting, the hepatic expression of Lpl (lipoprotein lipase) was increased in Fads1 ASO treatment (Figure 6R ), which may contribute to the dyslipidemia seen in Fads1 knockdown mice. However, Fads1 ASO treatment promoted hypercholesterolemia under both dietary settings, characterized by significant increases in LDL cholesterol levels ( Figure 3I ) without altering very LDL cholesterol levels ( Figure 3H ). The previously reported ability of the ω-3 PUFA substrate diet to increase high-density lipoprotein cholesterol levels 22 was abolished by Fads1 knockdown ( Figure 3J ), indicating that endogenous EPA biosynthesis is necessary for this phenotype. In addition to alterations in plasma lipid levels, Fads1 knockdown resulted in diet-specific reorganization of circulating leukocyte populations. In saturated fat-fed mice, Fads1 knockdown reduced Ly6C
High monocytes, and similarly reduced both CD4 + and CD8 + T cell populations ( Figure 3K through 3P) . When challenged with the ω-3 PUFA substrate diet Fads1 ASO-treated mice exhibited elevations in Ly6C
High and Ly6C Low monocytes and neutrophils, without significant alterations in T cell populations ( Figure 3K through 3P) . Collectively, these data suggest that Fads1-driven Δ-5 desaturation balances proatherogenic dyslipidemia and monocytosis in a diet-specific manner (Figure 3 ).
Fads1 Impacts Macrophage-Driven Inflammation and Resolution Programs Both In Vitro and In Vivo
Macrophages are requisite players in the pathogenesis of atherosclerosis, playing important roles in both the initiation and resolution phases of the disease progression. 23 Whereas classically M1 activated macrophages are generally proinflammatory in nature, alternatively activated M2 macrophages are thought to be involved in the resolution of inflammation during plaque regression and stabilization. 24 To address the role of Fads1 in macrophage phenotype switching, we elicited peritoneal macrophages from ASO-treated mice, and acutely induced polarization programs with M1 (lipopolysaccharide [LPS]) or M2 (interleukin 4, IL-4) stimuli (Figure 4) . It is important to note that Fads1 mRNA expression was suppressed by LPS treatment (Figure 4A ), yet was increased by IL-4 treatment ( Figure 4F ). Fads1 knockdown in macrophages was associated with skewing toward M1 and away from M2 polarization (Figure 4) . In support of this, Fads1 knockdown resulted in augmented LPS-driven proinflammatory gene expression ( Figure 4A through 4E ), yet was associated with diminished IL-4-driven alternative activation gene signatures ( Figure 4F through 4J) . The expression of AA and EPA oxidizing enzymes Cox-1 (cyclooxygenases 1) and 2 (Cox-2) and Alox12 (12-lipoxygenase) were differentially expressed with Fads1 knockdown under certain stimulated conditions ( Figure 4D , 4E, 4I, and 4J). Fads1 knockdown in macrophages was also associated with generally lower levels of lipid mediators originating from oxidation of AA, EPA, and DHA ( Figure 4K ). Given that Fads1 knockdown was associated with such striking diversification of lipid mediators both in isolated macrophages ( Figure 4K ) and in the liver (Figure 1F Figure VIIE and VIIF in the online-only Data Supplement). Also, blood glucose levels were negatively associated with the DHA-derived lipid mediators 17-hydroxydocosahexaenoic acid (R 2 =0.5001, P=0.0005) and 21-hydroxydocosahexaenoic acid (R 2 =0.3468, P=0.006; Figure VIIG and VIIH in the online-only Data Supplement). Collectively, these data suggest that Fads1 plays an underappreciated role in macrophage polarization and lipid mediator production, and provide initial clues into potential Fads1-regulated lipid mediators driving diverse cardiometabolic phenotypes.
To further investigate the role of Fads1 in orchestrating proinflammatory and proresolving macrophage programs in vivo, we treated diet-fed control and Fads1 knockdown mice with M1 (LPS) or M2 (IL-4) skewing stimuli and followed acute inflammatory responses in the circulation, liver, and aortic arch ( Figure 5 ). Fads1 knockdown did not appreciably alter plasma cytokine levels under IL-4-stimulated conditions (data not shown), but did significantly alter LPS-stimulated plasma cytokine responses. Although Fads1 knockdown did not alter the early LPS-induced burst of circulating TNF-α (tumor necrosis factor α), Fads1 ASO treatment was associated with significantly elevated LPS-stimulated levels of several interleukins (IL-1β, IL-12p70, and IL-10) after 6 hours ( Figure 5A through 5D ). In the liver, Fads1 knockdown was associated with increased expression of the macrophage marker genes F4/80 and Cd68, and this effect was particularly apparent in mice fed the ω-3 substrate diet ( Figure 5F and 5G). Fads1 knockdown in the liver was associated with reduced expression of the M2 marker gene arginase 1 under all conditions ( Figure 5H ). In contrast, Fads1 knockdown enhanced LPS-stimulated expression of macrophage-derived cytokines including MCP-1, MIP-1α, and TNF-α ( Figure 5I  through 5K ), yet modestly blunted expression of the acute phase protein SAA (serum amyloid A) in ω-3 substrate diet-fed mice ( Figure 5L ). In the aortic arch, there was a roughly 50% knockdown of Fads1 with Fads1 ASO treatment, and much like what was seen in elicited macrophages ( Figure 4A ), LPS alone suppressed Fads1 expression by 50% when compared with saline injected mice ( Figure 5M ). Fads1 knockdown in the aortic arch was associated with increased expression genes encoding macrophage markers such as F4/80 and Cd11b, particularly in the ω-3 substrate diet groups ( Figure 5N and 5O) . Furthermore, Fads1 knockdown was associated with diet-specific effects on both LPSand IL-4-stimulated cytokine expression in the aortic arch ( Figure 5P through 5T) . Collectively, these results suggest that Fads1 regulates systemic inflammation, tissue macrophage abundance, and macrophage polarization in vivo in a highly gene-and tissue-specific manner.
Fads1 Determines the Reciprocal Regulation of Inflammation and Lipogenesis Driven by LXR
The nuclear hormone receptor LXR is a well-known regulator of tissue inflammation, atherosclerosis, cholesterol balance, de novo lipogenesis, and membrane PUFAdiversification. [25] [26] [27] [28] [29] [30] Given that our results here link Fads1 to these same phenotypes we hypothesized that Fads1 may be an important effector of LXR signaling. To test this, we examined LXR agonist-induced metabolic reprogramming in control and Fads1 knockdown mice maintained on a chow diet ( Figure 6 ). Fads1 knockdown was associated with enhanced basal and LXR-stimulated fecal neutral sterol loss, yet was associated with blunted basal and LXR-stimulated liver triglyceride levels ( Figure 6A and 6B) . In contrast to these LXR-associated lipid phenotypes, the ability of Fads1 knockdown to alter hepatic cholesterol levels was largely independent of LXR activation state ( Figure 6C through 6E) . However, Fads1 knockdown significantly increased plasma cholesterol only in animals treated with pharmacological LXR agonist ( Figure 6F ). Knockdown of Fads1 did not significantly alter the hepatic expression of LXRα itself (data not shown), but did result in selective alterations in LXRstimulated gene expression ( Figure 6G through 6R ). For instance, the ability of the LXR agonist T0901317 to increase the expression of Srebp1c and its target genes (Fas, Scd1, and Acc1) was blunted in Fads1 knockdown mice ( Figure 6K  through 6N ). In parallel, LXR-stimulated expression of genes involved in cholesterol efflux (ATP-binding cassette transporters G5 and G8) and phosphatidylcholine remodeling (lysphosphatidylcholine acyltransferase) were also blunted in Fads1 knockdown mice ( Figure 6O through 6Q) . However, not all LXR-stimulated gene expression was blunted in Fads1 knockdown mice, as was the case for lipoprotein lipase (Lpl; Figure 6R ). The hepatic expression of Hmgcr (HMG-CoA reductase) and Hmgcs1 (HMG-CoA synthase) were increased in both the basal and LXR-stimulated state ( Figure 6I and 6J) . However, Fads1 knockdown only increased hepatic expression of Srebp2 in the T0901317-treated mice ( Figure 6H ). These results suggest that Fads1 is an effector of LXR agonist-driven transcriptional control of fatty acid and cholesterol metabolic programs in the liver.
Discussion
Cardiometabolic diseases including obesity, insulin resistance, atherosclerosis, and steatohepatitis all share tissuespecific features of chronic unresolved inflammation. [31] [32] [33] [34] Although often underappreciated, membrane PUFA-derived lipid mediators play requisite roles in both the initiation and resolution phase of inflammation. There is a wealth of evidence showing beneficial effects of dietary PUFA supplementation on cardiometabolic diseases, [35] [36] [37] yet the specific contribution of endogenous PUFA synthesis driven by FADS1 (ie, AA and EPA generation) has been elusive. Here, we provide new evidence that Fads1-driven PUFA biosynthesis plays a role in cardiometabolic diseases associated with chronic unresolved inflammation (obesity, insulin resistance, atherosclerosis, and steatohepatitis). The main findings of the current study are (1) Fads1 is a major contributor to diet-driven enrichment of PUFAs in membrane phospholipids; (2) Fads1 loss of function results in diminished levels of AA-, EPA-, and DHA-derived proresolving lipid mediators; (3) Fads1 knockdown promotes hepatic inflammation in a diet-specific manner; (4) Fads1 knockdown promotes atherosclerosis in a diet-specific manner; (5) Fads1 knockdown results in the suppression of hepatic de novo lipogenesis; (6) Fads1 knockdown is associated with reduced adiposity and improved glucose tolerance; (7) Fads1 knockdown results in atherogenic dyslipidemia; (8) Fads1 activity impacts circulating monocyte and T cell levels in a diet-specific manner; (9) Fads1 reciprocally regulates M1 and M2 polarization programs in macrophages; (10) Fads1 is a tissue-specific effector of LPS-and IL-4-driven reprogramming of systemic inflammatory responses in vivo; and (11) Fads1 reciprocally regulates fatty acid and cholesterol reprogramming driven by the LXR. Collectively, these data support a model in which Fads1-driven AA and EPA production diversifies both proinflammatory and proresolving lipid mediator production to dictate proper inflammation initiation and resolution in cardiometabolic disease.
The FADS1-2-3 genetic locus is unique in that it shares genome-wide significant associations with almost all cardiometabolic phenotypes across the metabolic syndrome spectrum. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, the relative roles of the 3 separate enzymes (FADS1, FADS2, and FADS3) encoded at this locus in driving cardiometabolic disease has been elusive.
This study provides the first evidence that specific loss of the Δ-5 desaturase FADS1 can dynamically alter many of the cardiometabolic phenotypes originally identified in human genome-wide association studies. However, it is important to compare and contrast our findings to a recent article describing cardiometabolic phenotypes in a gene trap Fads1 loss of function mouse model. 38 The study by Powell and colleagues reported similar improvements in body weight and glucose tolerance with Fads1 loss of function, but also reported modest reductions in atherosclerotic burden in Fads1 loss of function mice on an apolipoprotein E-null background. 38 Given these discrepant results, it is essential to note that hepatic expression levels of Fads1 were not reported in the study by Powell et al, 38 and AA and EPA levels were very modestly reduced in their Fads1 targeted mice. In fact, the authors speculate that this model produced a hypomorphic allele rather than a complete loss of function allele. Furthermore, the study by Powell et al 38 is complicated by the fact that mice were studied on diets containing supplemental AA, thereby potentially masking the phenotypes driven by lack of endogenous AA production. Furthermore, a major difference between the current studies and the study by Powell et al 38 is the use of different hyperlipidemic mouse models. Whereas atherosclerosis in the Ldlr −/− model used here is mainly driven by very LDL and LDL accumulation, the more rapid atherosclerosis progression in apoE −/− mice is driven largely by the accumulation of intestinally-derived apoB-containing lipoproteins. Given early postnatal lethality of global Fads1 knockout mice, 19, 20 and obvious limitations of genetic hypomorphs and ASO-mediated knockdown, additional tissuespecific genetic approaches will ultimately be necessary to fully understand the cell autonomous roles of Fads1 in cardiometabolic disease. It is important to note that the ASO knockdown approach used here does not accurately reflect the anticipated effect of common FADS1 polymorphisms. In fact, ASOs typically only achieve appreciable knockdown in the liver, adipose, kidney, and some cells with the reticuloendothelial cell system, whereas the human FADS1 variants likely affect expression across all tissues. Moving forward it will be important to study each individual FADS1 SNP using non-ASO genetic approaches to fully understand the functional consequences of the cardiometabolic disease-associated variants.
Given the fact that Fads1 knockdown dramatically reorganizes membrane phospholipids as well as diversifies downstream oxidation products of AA, EPA, and DHA (Figures 1  and 2) , it is challenging to define a single unifying mechanistic link between Δ-5 desaturation and cardiometabolic disease phenotypes. In fact, it is most likely that certain lipid mediator alterations seen in Fads1 knockdown mice may drive specific aspects of the phenotype. For instance, recent study has shown that vulnerable regions within human atherosclerotic plaques exhibit a lower SPM to leukotriene ratio similar to what is seen with Fads1 knockdown ( Figure 1J) . 31, 39 Moreover, direct administration of resolvin D1 (which is reduced in Fads1 ASO-treated mice, Figure 1F through 1J) promotes features of atherosclerotic plaque stability (eg, increased fibrous cap thickness) in mice. 31 Furthermore, the AA-derived lipid mediator lipoxin A 4 , which is severely reduced in Fads1 ASOtreated mice (Figure 1F through 1J; Figure IIC in the onlineonly Data Supplement), has been shown to limit chronic inflammation in adipose tissue and liver. [40] [41] [42] Importantly, Fads1's ability to alter lipid mediator balance is very dependent on dietary provision of substrate fatty acids (Figure 1F through 1J; Figure II in the online-only Data Supplement). In support of this concept, Fads1 knockdown has minimal effects on phospholipid acyl chain composition when a primary saturated fat source is provided, yet when a diet enriched in 18 carbon length ω-3 fatty acid precursors is fed, Fads1 knockdown is associated with striking alterations in membrane phospholipids (Figure 1D These results suggest that FADS1 activity becomes particularly important in lipid mediator balance under dietary conditions where precursor essential fatty acid substrates for long-chain PUFA biosynthesis are provided.
Another important finding of this study is that Fads1 is novel effector of LXR signaling in vivo, reciprocally balancing LXR-driven increases in fecal cholesterol disposal and de novo lipogenesis ( Figure 6 ). Additional study is needed to understand how Fads1-driven AA-and EPA-derived lipid mediators impact reverse cholesterol transport and fatty acid biosynthesis, but in line with our observations a recent report linked the AA-derived metabolome to reverse cholesterol transport in mice and humans. 43 Furthermore, AA has also been shown to inhibit LXR-driven transactivation of the SREBP1c promoter, thereby impacting several downstream lipid signaling pathways in cells. 44 Based on these collective observations, it is tempting to speculate that AA itself, or more likely some downstream oxidative metabolite of AA, allows for coordinated regulation of LXR, SREBP1c, and PPARα signaling to balance lipid metabolic and inflammatory transcriptional programs. However, when considering the ability of Fads1 to alter LXR signaling in our studies it is important to note that we studied LXR activation in different dietary cholesterol levels and genetic backgrounds. For instance, all studies examining effects of Fads1 knockdown on atherosclerosis and hepatic inflammation (Figures 1 through 5) were done in Ldlr −/− mice fed synthetic diets supplemented with 0.2% cholesterol, whereas the exogenous LXR agonist studies ( Figure 6 ) were done in chow-fed C57BL/6 mice. It has been demonstrated previously that dietary cholesterol levels can dramatically alter LXR target gene expression, with high dietary cholesterol providing substrate for endogenous oxysterol ligand production. 26, 45, 46 Therefore, the ability of Fads1 to alter LXR signaling is likely determined in part by dietary cholesterol levels. It is also important to note that the ability of Fads1 to alter hepatic cholesterol levels does not solely rely on its ability to alter LXR-driven transcriptional programs. In support of this, Fads1 ASO-driven increases in hepatic free cholesterol levels are apparent in both basal (vehicle) and LXR-stimulated (T0901317-treated) conditions ( Figure 6 ). Therefore, Fads1 likely impacts cholesterol homeostasis by LXR-dependent and independent mechanisms. One potential way that Fads1 could impact hepatic free cholesterol levels is by altering membrane phospholipid fatty acid composition to secondarily alter the stability of cholesterol-rich lipid rafts. It is well known that PUFA-enrichment in membrane phospholipids can have profound effects on lipid raft formation and stability. 47, 48 Our data suggest that under certain dietary conditions, Fads1 can be a major determinant of phospholipid fatty acid composition ( Figure 1D ). Therefore, we hypothesize that one plausible way Fads1 could alter hepatic FC levels in a LXR-independent manner may be by altering the stability of cholesterol-rich lipid raft domains. In summary, this study demonstrates that ASO-mediated knockdown of the Δ-5 desaturase Fads1 impacts many of the cardiometabolic phenotypes that were originally genetically linked to the FADS1-2-3 locus in a highly diet-specific manner. These findings highlight Fads1 as a regulator of inflammation initiation and resolution, and highlight the interplay between endogenous and exogenous (dietary) fatty acids in diseases characterized by unresolved inflammation.
